Skip to content

Cryoanalgesia vs. Epidural in the Nuss Procedure

Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02721017
Enrollment
20
Registered
2016-03-28
Start date
2016-05-31
Completion date
2018-09-30
Last updated
2021-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Funnel Chest, Pectus Excavatum

Keywords

Nuss, Nuss Procedure, pectus excavatum, cryoanalgesia

Brief summary

The purpose of this study is to determine whether cryoanalgesia provides better pain control for minimally invasive pectus excavatum repair (the Nuss procedure) than thoracic epidural.

Detailed description

Pain control is a major challenge for physicians, who must ensure appropriate and effective pain control for their patients, while remaining mindful of the many negative effects of opioid dependence and addiction. Nowhere is there a more pressing need than in children and young adults, who are at high risk for drug abuse, and in post-operative care, since post-operative opioid use can be a starting point for long-term pain issues. Postoperative pain control in the Nuss procedure, minimally invasive repair of the congenital chest wall deformity known as pectus excavatum, remains a significant problem for the 3000 patients who undergo this procedure each year, mostly adolescents and young adults. Many multimodal analgesic regimens have been tried, but optimal treatment remains unknown. This study will test a novel and promising strategy of using intra-operative cryoanalgesia during the Nuss procedure. Cryoanalgesia is the localized, temporary freezing of peripheral nerves, which is performed at the time of the Nuss procedure. The study is a 20-subject prospective, randomized pilot trial comparing cryoanalgesia to thoracic epidural analgesia for post-operative pain control in patients undergoing the Nuss procedure. Subjects will be recruited from patients already scheduled for a Nuss procedure at our institution, and will undergo 1:1 randomization to either cryoanalgesia or thoracic epidural analgesia for perioperative pain control. During their hospitalization, patients' opiate usage will be prospectively recorded, and pain will be assessed twice per day. Upon discharge, patients will maintain a log of their opiate use, and will return to clinic at 2 weeks, 1 month, 3 months, and 1 year after Nuss procedure for post-operative assessment. Primary outcome is length of perioperative hospitalization, an objective measure that synthesizes many different aspects of a procedure and its subsequent post-operative course, including pain control. Secondary outcomes are post-operative narcotic usage and direct cost of perioperative hospitalization. Side effects of both interventions will also be assessed. This will be the first systematic investigation of cryoanalgesia for local nerve block in a thoracoscopic procedure, and the first study involving its use in adolescents and young adults. The results will have direct application for those undergoing the Nuss procedure to repair pectus excavatum. Investigators will also delineate a reproducible protocol for delivering cryoanalgesia thoracoscopically, to ensure others can safely and effectively use this method if it proves beneficial. Although the focus is on the small subset of patients who undergo the Nuss procedure, if a standardized approach to cryoanalgesia delivery in a thoracoscopic procedure has a positive effect on patient outcomes and cost of hospitalization, the technique could be applied to a variety of surgical procedures, as well as for other neuropathic pain.

Interventions

DRUGThoracic epidural (ropivicaine, fentanyl)

Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Food and Drug Administration (FDA)
CollaboratorFED
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* scheduled for Nuss procedure for pectus excavatum correction * at least 13 years old at the time of the procedure

Exclusion criteria

* age less than 13 years at time of procedure * use of pain medication prior to procedure * pectus carinatum, Poland's syndrome, or any chest wall anomaly other than pectus excavatum * previous repair of pectus excavatum by any technique * previous thoracic surgery * congenital heart disease * bleeding dyscrasia * major anesthetic risk factors or history of previous problem with anesthesia * pregnancy * inability to communicate in English

Design outcomes

Primary

MeasureTime frameDescription
Length of Hospitalizationestimated one week or lessthe length of the patient's in-hospital stay following admission for Nuss procedure

Secondary

MeasureTime frameDescription
Narcotic UsagePost Operative Hospital StayInpatient narcotic usage
Mean Neuropathic Pain Score at One Yearone yearNeuropathic specific pain (described as burning, electrical or tingling sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).
Cost Analysisestimated one weekcost analysis of initial hospitalization following Nuss procedure

Countries

United States

Participant flow

Recruitment details

Twenty consecutive patients were recruited from those scheduled for the Nuss procedure.

Pre-assignment details

Exclusion criteria were age \<13 years, chest wall anomaly other than pectus excavatum, previous repair or other thoracic surgery, and chronic use of pain medications.

Participants by arm

ArmCount
Cryoanalgesia
Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure Cryoanalgesia
10
Thoracic Epidural
Thoracic epidural (ropivicaine, fentanyl). Thoracic epidural (ropivicaine, fentanyl): Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
10
Total20

Baseline characteristics

CharacteristicThoracic EpiduralTotalCryoanalgesia
Age, Categorical
<=18 years
7 Participants11 Participants4 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
3 Participants9 Participants6 Participants
Age, Continuous16.1 years18.5 years20.9 years
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
10 Participants20 Participants10 Participants
Sex: Female, Male
Female
2 Participants3 Participants1 Participants
Sex: Female, Male
Male
8 Participants17 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 10
other
Total, other adverse events
0 / 100 / 10
serious
Total, serious adverse events
0 / 102 / 10

Outcome results

Primary

Length of Hospitalization

the length of the patient's in-hospital stay following admission for Nuss procedure

Time frame: estimated one week or less

ArmMeasureValue (MEDIAN)
CryoanalgesiaLength of Hospitalization3 Length of Stay (Post-Operative Days)
Thoracic EpiduralLength of Hospitalization5 Length of Stay (Post-Operative Days)
Secondary

Cost Analysis

cost analysis of initial hospitalization following Nuss procedure

Time frame: estimated one week

Population: Cost analysis was not performed, as these data were not collected.

Secondary

Mean Neuropathic Pain Score at One Year

Neuropathic specific pain (described as burning, electrical or tingling sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).

Time frame: one year

ArmMeasureValue (MEAN)Dispersion
CryoanalgesiaMean Neuropathic Pain Score at One Year2.4 score on a scaleStandard Deviation 2.69
Thoracic EpiduralMean Neuropathic Pain Score at One Year1.9 score on a scaleStandard Deviation 1.34
Secondary

Narcotic Usage

Inpatient narcotic usage

Time frame: Post Operative Hospital Stay

ArmMeasureValue (MEAN)Dispersion
CryoanalgesiaNarcotic Usage268 mgStandard Deviation 165.2
Thoracic EpiduralNarcotic Usage684 mgStandard Deviation 191.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026